|
 The study, known as "EAGLE", did not improve overall survival
compared with standard chemotherapy in patients with the
hard-to-treat disease, the company said.
The results come after AstraZeneca warned last month that its
immunotherapy treatment Imfinzi did not meet the main goal of
improving survival rates for patients with the most advanced form of
lung cancer, putting pressure on its shares.
AstraZeneca has been seen as having a head start in the race for
cancer treatments, and Imfinzi was aiming to be the new standard of
care in treating early inoperable stage III lung cancer.
[to top of second column] |
"While these results are disappointing, we remain committed to
evaluating the potential of Imfinzi and other innovative medicines
for patients with head and neck cancer," said Chief Medical Officer
Sean Bohen.
The trial was conducted at 169 centers across 24 countries including
the U.S., Europe, South America, Japan, Korea, Taiwan, Israel and
Australia, AstraZeneca said.
(Reporting by Sangameswaran S and Noor Zainab Hussain in Bengaluru;
Editing by Sai Sachin Ravikumar, Bernard Orr)
[© 2018 Thomson Reuters. All rights
reserved.] Copyright 2018 Reuters. All rights reserved. This material may not be published,
broadcast, rewritten or redistributed.
Thompson Reuters is solely responsible for this content. |
